Universität zu Köln

Eichhorst, Barbara, Cramer, Paula and Hallek, Michael (2016). Initial therapy of chronic lymphocytic leukemia. Semin. Oncol., 43 (2). S. 241 - 251. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1532-8708

Full text not available from this repository.

Abstract

Only chronic lymphocytic leukemia (CLL) patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. Prognostic risk factor profile and comorbidity burden are most relevant for the choice of treatment. For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab remains the current standard therapy. For unfit patients, treatment with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) plus milder chemotherapy (chlorambucil) may be applied. Patients with a del(17p) or TP53 mutation should be treated with the kinase inhibitors ibrutinib or a combination of idelalisib and rituximab. Clinical trials over the next several years will determine, whether kinase inhibitors, other small molecules, immunotherapeutics, or combinations thereof will further improve outcomes for patients with CLL. (C) 2016 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Cramer, Paula UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-279635
DOI:	10.1053/j.seminoncol.2016.02.005
Journal or Publication Title:	Semin. Oncol.
Volume:	43
Number:	2
Page Range:	S. 241 - 251
Date:	2016
Publisher:	W B SAUNDERS CO-ELSEVIER INC
Place of Publication:	PHILADELPHIA
ISSN:	1532-8708
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; TERM-FOLLOW-UP; HIGH-RISK; ELDERLY-PATIENTS; OPEN-LABEL; ANTI-CD20 ANTIBODY; 1ST-LINE TREATMENT Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27963